{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:32Z","timestamp":1787671832192,"version":"build-2736575974"},"reference-count":50,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The therapeutic landscape of complement inhibition has recently expanded considerably. However, most approved agents specifically target single complement components systemically, which can result in limited functional effects. In fact, stoichiometric inhibition has shown limitations both in vitro and in vivo. In this study, we evaluated, to our knowledge, for the first time the in vivo efficacy of \u201ctriple-fusion\u201d (TriFu), an engineered fusion protein comprising key domains of 3 natural complement regulators, CD55, factor H, and CD35, including a host-recognition motif. In a rat xenotransfusion model, TriFu provided favorable protection of transfused human red blood cells compared to C5 inhibition by Ornithodoros moubata complement inhibitor, prolonging circulation time on par with cobra venom factor\u2013mediated complement depletion and completely inhibiting C3 opsonization. Furthermore, TriFu treatment improved multiple clinical inflammatory parameters (eg, interleukin-6 and tumor necrosis factor \u03b1). These findings suggest that regulatory modulation of complement could offer advantages over C5 inhibition, providing a more balanced and adaptive therapeutic approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020033","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:01:06Z","timestamp":1781204466000},"page":"5722-5733","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion"],"prefix":"10.1182","volume":"10","author":[{"given":"Susa","family":"Savukoski","sequence":"first","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Maria","family":"Dettner","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Schultze","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7697-2962","authenticated-orcid":false,"given":"Christoph","family":"Gerber","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9816-4067","authenticated-orcid":false,"given":"Michael Stefan","family":"Steinberger","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-2076","authenticated-orcid":false,"given":"Rebecca","family":"Halbgebauer","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5689-613X","authenticated-orcid":false,"given":"Peter","family":"Melter","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dopler","sequence":"additional","affiliation":[{"name":"2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Palmer","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-3251","authenticated-orcid":false,"given":"Christian Karl","family":"Braun","sequence":"additional","affiliation":[{"name":"3Department for Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany"},{"name":"4German Center for Child and Adolescent Health, Partner Site Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hafner","sequence":"additional","affiliation":[{"name":"2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0057-2730","authenticated-orcid":false,"given":"Bo","family":"Nilsson","sequence":"additional","affiliation":[{"name":"5Department of Immunology, Genetics and Pathology, Rudbeck Laboratory C5:3, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Nilsson-Ekdahl","sequence":"additional","affiliation":[{"name":"5Department of Immunology, Genetics and Pathology, Rudbeck Laboratory C5:3, Uppsala, Sweden"},{"name":"6Linnaeus Centre of Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5785-802X","authenticated-orcid":false,"given":"Tom Eirik","family":"Mollnes","sequence":"additional","affiliation":[{"name":"7Department of Immunology, Oslo University Hospital, University of Oslo, Oslo, Norway"},{"name":"8Research Laboratory, Nordland Hospital, Bodo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-9742","authenticated-orcid":false,"given":"Raban","family":"Heller","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"},{"name":"9Department for Trauma Surgery, Orthopaedics, Reconstructive and Septic Surgery, and Sports Traumatology, German Armed Forces Hospital Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6659","authenticated-orcid":false,"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"10Institute of Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Wuerttemberg-Hessen and University Hospital Ulm, Ulm, Germany"},{"name":"11Institute of Transfusion Medicine, University Hospital Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Q.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S.","family":"Huber-Lang","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4875-8275","authenticated-orcid":false,"given":"Marco","family":"Mannes","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026082510521091600_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4614-4118-2_10","article-title":"Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies","volume":"735","author":"Risitano","year":"2013","journal-title":"Adv Exp Med Biol"},{"issue":"17","key":"2026082510521091600_bib2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"2026082510521091600_bib3","doi-asserted-by":"crossref","first-page":"102979","DOI":"10.1016\/j.jaut.2022.102979","article-title":"The complement system and human autoimmune diseases","volume":"137","author":"Coss","year":"2023","journal-title":"J Autoimmun"},{"issue":"14","key":"2026082510521091600_bib4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/bph.15245","article-title":"Complement in trauma\u2014traumatised complement?","volume":"178","author":"Huber-Lang","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2026082510521091600_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00281-021-00872-x","article-title":"Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis","volume":"43","author":"Mannes","year":"2021","journal-title":"Semin Immunopathol"},{"issue":"25","key":"2026082510521091600_bib6","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2026082510521091600_bib7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood.2023021762","article-title":"Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria","volume":"143","author":"Kelly","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026082510521091600_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"issue":"10424","key":"2026082510521091600_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"2026082510521091600_bib10","doi-asserted-by":"crossref","first-page":"100079","DOI":"10.1016\/j.pharmr.2025.100079","article-title":"The complement system: biology, pathology, and therapeutic interventions","volume":"77","author":"Li","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"12","key":"2026082510521091600_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0167-5699(88)91240-6","article-title":"The multifunctional role of C3, the third component of complement","volume":"9","author":"Lambris","year":"1988","journal-title":"Immunol Today"},{"issue":"4","key":"2026082510521091600_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ki.1988.214","article-title":"Metabolism of complement factor D in renal failure","volume":"34","author":"Pascual","year":"1988","journal-title":"Kidney Int"},{"issue":"1","key":"2026082510521091600_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/imr.13164","article-title":"Protein therapeutics and their lessons: expect the unexpected when inhibiting the multi-protein cascade of the complement system","volume":"313","author":"Schmidt","year":"2023","journal-title":"Immunol Rev"},{"issue":"8","key":"2026082510521091600_bib14","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026082510521091600_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026082510521091600_bib16","doi-asserted-by":"crossref","first-page":"105784","DOI":"10.1016\/j.jbc.2024.105784","article-title":"Triple-fusion protein (TriFu): a potent, targeted, enzyme-like inhibitor of all three complement activation pathways","volume":"300","author":"Sonnentag","year":"2024","journal-title":"J Biol Chem"},{"issue":"11","key":"2026082510521091600_bib17","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/trf.12695","article-title":"Complement inhibition significantly decreases red blood cell lysis in a rat model of acute intravascular hemolysis","volume":"54","author":"Shah","year":"2014","journal-title":"Transfusion"},{"issue":"8","key":"2026082510521091600_bib18","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/trf.13674","article-title":"Peptide inhibitor of complement C1 modulates acute intravascular hemolysis of mismatched red blood cells in rats","volume":"56","author":"Kumar","year":"2016","journal-title":"Transfusion"},{"issue":"4","key":"2026082510521091600_bib19","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4049\/jimmunol.174.4.2084","article-title":"Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata","volume":"174","author":"Nunn","year":"2005","journal-title":"J Immunol"},{"issue":"20","key":"2026082510521091600_bib22","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/bloodadvances.2023010817","article-title":"Complement and platelets: prothrombotic cell activation requires membrane attack complex induced release of danger signals","volume":"7","author":"Mannes","year":"2023","journal-title":"Blood Adv"},{"key":"2026082510521091600_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fimmu.2018.00179","article-title":"Characterization of renal injury and inflammation in an experimental model of intravascular hemolysis","volume":"9","author":"Merle","year":"2018","journal-title":"Front Immunol"},{"issue":"17","key":"2026082510521091600_bib24","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2026082510521091600_bib25","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1182\/bloodadvances.2019031591","article-title":"Absence of complement component 3 does not prevent classical pathway\u2013mediated hemolysis","volume":"3","author":"Zhang","year":"2019","journal-title":"Blood Adv"},{"issue":"33","key":"2026082510521091600_bib26","doi-asserted-by":"crossref","first-page":"eabo2341","DOI":"10.1126\/sciadv.abo2341","article-title":"Complement C3 inhibition in severe COVID-19 using compstatin AMY-101","volume":"8","author":"Skendros","year":"2022","journal-title":"Sci Adv"},{"issue":"4","key":"2026082510521091600_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood.2024027574","article-title":"Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice","volume":"146","author":"Fattizzo","year":"2025","journal-title":"Blood"},{"key":"2026082510521091600_bib28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3389\/fimmu.2019.01639","article-title":"Different levels of incomplete terminal pathway inhibition by eculizumab and the clinical response of PNH patients","volume":"10","author":"Harder","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"2026082510521091600_bib29","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.toxicon.2010.04.007","article-title":"Cobra venom factor: structure, function, and humanization for therapeutic complement depletion","volume":"56","author":"Vogel","year":"2010","journal-title":"Toxicon"},{"issue":"29","key":"2026082510521091600_bib30","doi-asserted-by":"crossref","first-page":"30836","DOI":"10.1074\/jbc.M403196200","article-title":"Structure and function of recombinant cobra venom factor","volume":"279","author":"Kock","year":"2004","journal-title":"J Biol Chem"},{"issue":"1","key":"2026082510521091600_bib31","doi-asserted-by":"crossref","first-page":"10346","DOI":"10.1038\/s41598-018-28724-z","article-title":"Cobra venom factor-induced complement depletion protects against lung ischemia reperfusion injury through alleviating blood-air barrier damage","volume":"8","author":"Haihua","year":"2018","journal-title":"Sci Rep"},{"issue":"19","key":"2026082510521091600_bib32","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2026082510521091600_bib33","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2026082510521091600_bib34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2026082510521091600_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bcmd.2014.11.021","article-title":"Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria","volume":"54","author":"Seregina","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"2026082510521091600_bib36","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1111\/petr.12290","article-title":"Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation","volume":"18","author":"Ranch","year":"2014","journal-title":"Pediatr Transpl"},{"issue":"4","key":"2026082510521091600_bib37","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2026082510521091600_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/imm.13229","article-title":"Complement activation by human IgG antibodies to galactose-\u03b1-1,3-galactose","volume":"161","author":"Bernth Jensen","year":"2020","journal-title":"Immunology"},{"issue":"12","key":"2026082510521091600_bib39","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/01.TP.0000441091.47464.c6","article-title":"Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads","volume":"97","author":"Schwaiger","year":"2014","journal-title":"Transplantation"},{"issue":"12","key":"2026082510521091600_bib43","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026082510521091600_bib44","first-page":"3471","article-title":"Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome","volume":"130","author":"McKinley","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2026082510521091600_bib45","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2026082510521091600_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.chom.2016.05.023","article-title":"Dual-track clearance of circulating bacteria balances rapid restoration of blood sterility with induction of adaptive immunity","volume":"20","author":"Broadley","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"3077","key":"2026082510521091600_bib47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1126\/science.118.3077.733","article-title":"The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis","volume":"118","author":"Nelson","year":"1953","journal-title":"Science"},{"issue":"1","key":"2026082510521091600_bib49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12890-020-01307-3","article-title":"Pretreatment with atorvastatin ameliorates cobra venom factor-induced acute lung inflammation in mice","volume":"20","author":"Guo","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"8","key":"2026082510521091600_bib50","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.intimp.2006.03.002","article-title":"Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats","volume":"6","author":"Proctor","year":"2006","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2026082510521091600_bib51","doi-asserted-by":"crossref","first-page":"31365","DOI":"10.1038\/srep31365","article-title":"Stratification of responders towards eculizumab using a structural epitope mapping strategy","volume":"6","author":"Volk","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"2026082510521091600_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/imm.13228","article-title":"Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5","volume":"161","author":"Zelek","year":"2020","journal-title":"Immunology"},{"issue":"4965","key":"2026082510521091600_bib53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1126\/science.2371562","article-title":"Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis","volume":"249","author":"Weisman","year":"1990","journal-title":"Science"},{"issue":"5","key":"2026082510521091600_bib54","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4049\/jimmunol.149.5.1736","article-title":"Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo","volume":"149","author":"Moran","year":"1992","journal-title":"J Immunol"},{"issue":"1","key":"2026082510521091600_bib55","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1038\/s41598-021-01423-y","article-title":"A potent truncated form of human soluble CR1 is protective in a mouse model of renal ischemia\u2013reperfusion injury","volume":"11","author":"Bongoni","year":"2021","journal-title":"Sci Rep"},{"key":"2026082510521091600_bib56","doi-asserted-by":"crossref","first-page":"102687","DOI":"10.1016\/j.coi.2025.102687","article-title":"Local complement inhibition by selective precision-targeted therapies","volume":"98","author":"Wang","year":"2026","journal-title":"Curr Opin Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5722\/2538181\/blooda_adv-2026-020033-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5722\/2538181\/blooda_adv-2026-020033-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:55:47Z","timestamp":1787669747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5722\/569104\/In-vivo-evidence-of-effective-complement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":50,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020033","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,17]]}}}